Abstract: The aim of this opinion paper is to point out the knowledge gap between evidence on the molecular level and clinical diagnostic possibilities in left ventricular hypertrophy (LVH) regarding the prediction of ventricular arrhythmias and monitoring the effect of therapy. LVH is defined as an increase in left ventricular size and is associated with increased occurrence of ventricular arrhythmia. Hypertrophic rebuilding of myocardium comprises interrelated processes on molecular, subcellular, cellular, tissue, and organ levels affecting electrogenesis, creating a substrate for triggering and maintaining arrhythmias. The knowledge of these processes serves as a basis for developing targeted therapy to prevent and treat arrhythmias. In the clinical practice, the method for recording electrical phenomena of the heart is electrocardiography. The recognized clinical electrocardiogram (ECG) predictors of ventricular arrhythmias are related to alterations in electrical impulse propagation, such as QRS complex duration, QT interval, early repolarization, late potentials, and fragmented QRS, and they are not specific for LVH. However, the simulation studies have shown that the QRS complex patterns documented in patients with LVH are also conditioned remarkably by the alterations in impulse propagation. These QRS complex patterns in LVH could be potentially recognized for predicting ventricular arrhythmia and for monitoring the effect of therapy.

Keywords: left ventricular hypertrophy; ventricular arrhythmia; electrical remodeling; non-specific ECG predictors; QRS complex morphology

1. Introduction

Ventricular arrhythmias, especially ventricular tachycardia and ventricular fibrillation, are life-threatening arrhythmias, frequently leading to sudden cardiac deaths. Therefore, identification of the arrhythmia predictors is of the utmost clinical importance.

There is rapid progress in the field of arrhythmology. It is the most growing part of electrocardiology, both in the basic science as well as in clinical electrocardiography and electrophysiology. There is an increasing body of knowledge and details on the substrate triggering and maintaining arrhythmias, such as changes in ion channels, action potentials, gap junctions, connexin, fibrosis, etc., revealing details on molecular mechanisms of ventricular arrhythmias. This knowledge of structural, functional, and electrical alterations serves as a background for identifying patients at risk of ventricular arrhythmias and creates a basis for development of risk stratification scores [1–5].

Ventricular arrhythmias, however, are manifestations of electrical instability. The unique method of recording electrical activity of the heart is electrocardiogram (ECG); in clinical practice, the standard 12-lead ECG is generally used.

There is a considerable gap between the detailed knowledge on the molecular level and the clinical possibilities and interpretation of ECG findings in evaluating the effect of antiarrhythmic therapy.
Reducing this gap is vital since the ultimate evaluation of any targeted antiarrhythmic therapy is based on the results of clinical studies.

Currently, there are several ECG findings that are recognized as ventricular arrhythmia predictors, and their interpretation is related to altered electrophysiological processes and to our understanding of ventricular arrhythmias mechanism. They are not specific for a certain clinical diagnosis and include, e.g., prolonged QRS complex duration, prolonged QT interval/corrected QT interval (QTc), early repolarization, and the fragmented QRS complex (fQRS).

In contrast, the progress and detailed knowledge in terms of electrogenesis are not reflected in the interpretation of P-QRS-T waveforms analysis, where the traditional interpretation still persists. The aim of this opinion paper is to discuss possible links between QRS complex morphology and ventricular arrhythmias based on molecular and electrophysiological processes and to discuss ECG patterns that could potentially indicate abnormal electrical substrate pertinent to conditions necessary for re-entry to occur. The links between ECG diagnostic criteria based on underlying processes affecting electrogenesis are demonstrated using an example of left ventricular hypertrophy (LVH).

2. Left Ventricular Hypertrophy

LVH is defined as an increase in the left ventricular size/left ventricular mass (LVM), and therefore the dominant methods for detecting the left ventricular (LV) anatomical enlargement are imaging methods.

Numerous studies have documented the association of anatomical left ventricular hypertrophy (LVH) with ventricular arrhythmias [6]. It was shown in the Framingham study [7] that the presence of echocardiographic LVH in the general screening population was associated with increased risk of ventricular arrhythmia. Hypertensive patients with LVH have higher risk of developing ventricular arrhythmias [8], and even in patients with mild to moderate arterial hypertension, the echocardiographic LVH, particularly eccentric LVH, is associated with higher risk of ventricular arrhythmia [9]. Higher risk of developing ventricular arrhythmias is documented in patients with valvular heart disease [10,11], which is reduced after surgical treatment [12].

In clinical practice, the term remodeling in relation to LVH is understood mainly on the anatomic scale and recognizes concentric remodeling, concentric hypertrophy, and eccentric hypertrophy. However, it is obvious that it is not the simple increase in LV size and/or LVM that creates conditions for arrhythmias. Triggering and maintaining arrhythmias require electrophysiological conditions, i.e., arrhythmogenic substrate that is generally referred to by the term electrical remodeling.

The hypertrophic rebuilding of myocardium is associated with a complex interrelated structural and functional rebuilding of ventricular myocardium, including complex changes in active and passive electrical properties. It is not a uniform process, but it shows considerable heterogeneity, including the size of hypertrophic cardiomyocytes [13,14], membrane currents [15], the connexin expression, as well in action potential characteristics [16,17].

The basic characteristic in LVH on the microscopic scale is the increase in size of individual cardiomyocytes documented in numerous animal and human studies. Additionally, the hypertrophied cardiomyocytes differ from the normal cardiomyocytes not only in diameter and length but also in branching and number of connected cardiomyocytes [18–21]. These structural changes affect upstroke velocity of the action potential, the action potential propagation, conduction velocity, and cell-to-cell impulse propagation [22–24].

An integral part of the hypertrophic rebuilding of myocardium is the considerable changes in interstitium. The main processes include fibrosis, inflammation, degenerative changes, and apoptosis [25]. Fibrosis is a diffuse process and can also create fibrous tissue depositions, creating localized areas, e.g., the mid-wall fibrosis described in patients with LVH [26,27]. Additionally, inflammation also creates localized areas of edema and accumulated blood cells [28,29]. Diffuse and localized areas of pathologically changed intercellular matrix contribute thus to the heterogeneity of
the electrical impulse propagation. These changes represent potentially arrhythmogenic substrate and correlate with ventricular arrhythmias and sudden cardiac death [30,31].

At the molecular level, an extensive body of evidence has been published. There are a variety of alterations in ion channels, gap junctions, connexin43, i.e., the dominant molecular processes affecting electrogenesis. For the relation of these processes to the QRS complex see e.g., [32].

Animal as well as human studies show a variety of results on the main depolarizing currents affecting the resting potential and the action potential configuration: the fast sodium current \( I_{Na} \), L-type calcium current \( I_{Ca(L)} \), and \( Na^+\)-\( Ca^{2+} \) exchanger \( I_{Na/Ca} \). A decrease in \( I_{Na} \) density has been documented [33,34], but on the other hand, its increase has also been described [35]. Similarly, a decrease in \( I_{Ca(L)} \) current has been shown [36,37], but an increase [38,39], or no difference has also been reported [40,41]. More consistent are findings regarding \( I_{Na/Ca} \), where an increase in \( I_{(Na/Ca)} \) density has been reported [33,42]. The ion channel remodeling is reviewed in detail by e.g., [43–46].

Alterations in ion channels are reflected in changes in resting membrane potential, as well as in action potential (AP). The results related to the depolarization phase of AP are not consistent. On one hand, no differences in resting membrane potential, the action potential upstroke velocity, or amplitude are documented [47,48]; on the other hand, significant changes are reported [39,49,50]. Also, there is not a consistent pattern in conduction velocity changes of hypertrophied cardiomyocytes [51,52]. The variety of results can be due to differences in experimental models of LVH, species and preparation employed, the severity of hypertrophy, methodological aspects, etc.; however, they create a solid base of evidence on the changes influencing electrical characteristics of hypertrophied cardiomyocytes and myocardium.

Gap junctions, the low-resistance intercellular structures, enable the functional connection between cardiomyocytes, and they are crucial for uninterrupted propagation of electrical impulse. The density and distribution of the gap junctions (GJ) in LVH are significantly changed, as has been documented in human studies and animal studies, including cell cultures and genetically modified models of LVH (Figures 1 and 2). The intercellular coupling is diminished and disorganized, creating a basis for altered ventricular activation, i.e., the structural and functional substrate for developing lethal arrhythmias [53–56].

Figure 1. Representative electron microscopic images of cardiomyocytes from the hypertrophied left ventricle of spontaneously hypertensive rats. Left panel: hypertrophied cardiomyocyte exhibiting electron-dense mitochondria (M) and well-preserved intercalated disc with adhesive junctions (AJ: fascia adherens and desmoses), as well as gap junctions (GJ), as indicated by arrows. Right panel: hypertrophied cardiomyocyte exhibiting severe subcellular injury including electro-lucent mitochondria, lysis of myofibrils, and rudimentary intercalated disc with remnant adhesive junction and missing gap junctions. Bar = 1 micrometer. myo: myofibril; esc: extracellular space.
Figure 2. Variations in gap junctions in hypertrophied left ventricle documented in spontaneously hypertensive rats, as identified by immunodetection of Cx43. A: Dominant Cx43 distribution in the intercalated discs (thin arrows); B: Dominant Cx43 distribution in lateral sites of the cardiomyocytes (thick arrows); C: Both lateral and intercalated disc distribution is seen (thick and thin arrows); D: Marked disordered Cx43 distribution in the fibrotic area. Thin arrows also indicate longitudinal orientation of the cardiomyocytes. Bar = 10 micrometers.

Connexin43 is the dominant isoform in the adult ventricles. Its expression and distribution in LVH is affected already in the early stage of LVH development, as is documented in animal and human studies, as well as in cultured cardiomyocytes [53,54,56–59]. Additionally, the gap junction conductance can be affected by additional factors such as pH and Ca$^{2+}$ ion concentration [60].

Structural and functional alterations at the molecular level lead to changes in active and passive electrical properties of myocardium. Their interrelation is presented in Figure 3. Regarding the action potential (AP) of the hypertrophied cardiomyocyte, changes in AP shape and duration depend on the functional expression of depolarizing and repolarizing currents [43,44]. The documented changes are mostly related to the repolarization phase, especially its prolongation [61,62]. However, there are significant changes also in the depolarization currents [32]. Additionally, it was shown that the process of uncoupling may also induce changes in AP duration [63].
3. Non-Specific ECG Predictors of Ventricular Arrhythmia in LVH

3.1. QRS Complex Duration

The prolonged QRS complex duration is a significant predictor of ventricular arrhythmia [64–66]. The interpretation of the relation between the prolonged QRS complex duration and occurrence of ventricular is quite straightforward and logical: the slowed activation of the ventricles (ventricular depolarization) prolongs the QRS complex duration, and pathophysiologically, the altered conduction of the ventricular myocardium is one of the characteristics of the arrhythmogenic substrate. In left ventricular hypertrophy, the QRS duration is prolonged and is associated with ventricular arrhythmia and sudden cardiac death [28,67,68]. Two main factors affect the QRS duration: anatomical—the increased left ventricular mass, i.e., a longer trajectory for the electrical impulse to pass; and functional—the slowed velocity of impulse propagation. The prolongation of the QRS complex, as well as the delayed intrinsicoid deflection via the leads V5/V6, is incorporated into the Romhilt-Estes score for LVH detection [69].

However, in cases when the increased QRS complex duration is associated with certain typical QRS morphology, the interpretation of these findings is shifted from the altered conduction of the ventricular myocardium to the conduction disorders of the conduction system—namely, to the ECG diagnosis of left bundle branch blocks (LBBB). These QRS patterns are also associated with a higher incidence of cardiac mortality in patients with LVH [70].

Using the term LBBB, the understanding of this typical QRS pattern is implicitly reduced to the block in the conduction system, and the alteration of the ventricular working myocardium is not considered. This modified assumption then contrasts with the finding of increased presence of the
conduction disorders with more severe ventricular hypertrophy or in myocardial infarction [71,72]. Using computer modeling, it was shown that the typical LBBB pattern can be a manifestation of slowed conduction velocity in the working myocardium, even when there is no block in the conduction system [73,74]. This is consistent with clinical findings of the increased association between LBBB patterns and clinical condition with severe alteration of working myocardium, such as severe LVH or myocardial infarction [75–77].

On the other hand, however, there are also conflicting results showing that the relation between QRS complex duration, conduction disorders, and ventricular arrhythmias is not that straightforward [78,79].

3.2. QT Interval

It has been shown that QT interval prolongation above the upper normal limits and variability of QT interval are associated with an increased risk of ventricular arrhythmia [80]. Both increased QT interval and QT dispersion have been found in LVH patients with different anatomical types [81,82] and are associated with the occurrence of ventricular arrhythmias and sudden cardiac deaths [83,84].

QT interval and QT dispersion are usually reported as parameters of repolarization. However, the QT intervals represent the time of both depolarization and repolarization. In clinical studies, less (or even no) attention is devoted to the contribution of the depolarization into the QT interval parameters.

In our simulation study [85], we presented the QT/QRS ratio with the aim to differentiate the QT prolongation due to primary depolarization prolongation (if the values of the ratio decreases) and repolarization prolongation (if the values of the ratio increases). The QT/QRS ratio was used in an experimental study [86] and was shown as a useful parameter in predicting potential risk of drug-induced ventricular arrhythmia. Later, Robyns et al. [87] showed its potential diagnostic usefulness in differentiating the predisposition to torsade de pointes (TdP) and non-TdP. The increase in the QT/QRS ratio was associated with the predisposition to TdP, and its decrease was associated with the predisposition for non-TdP-mediated VT/VF. Those results were not discussed in terms of pathophysiology, so considering a possible pathophysiological background, in the case of the predisposition to TdP, the increased QT/QRS ratio could point to the prolonged repolarization; and in the case of non-TdP-mediated VT/VF, the decrease in the QT/QRS ratio could point to the prolonged depolarization.

Technically, the QT interval is measured from the onset of the QRS complex to the end of the T wave, which could create a problem in cases with low amplitude T wave signal, both when manually as well as automatically measured. Very probably, this also contributes to the variety of recommended normal values.

Summarizing, it has been shown that QT interval as a predictor of ventricular arrhythmias has its potential; however, it has also its challenges in interpretation as well as in its precise measurement. [65,88].

3.3. Early Repolarization

Early repolarization (ER) refers to changes at the junction of the offset of the QRS complex and beginning of the ST segment: the J-waves or J-point elevation. It is frequently seen in young athletes, and it was shown to correlate with concentric remodeling. Although it is considered benign, it is assumed that it is related to structural and electric modifications induced by training [89]. Under pathological conditions, ER is associated with ventricular arrhythmia and sudden cardiac death [90–95]. It is assumed that the pathophysiological mechanism triggering ventricular arrhythmias is the regional heterogeneity of cardiomyocytes refractoriness caused by alteration of repolarizing currents, including local differences in I_{to} current density [96–98]. However, controversial results are also reported [99].

The definitions of the ECG findings in ER vary; additionally, the ER abnormalities are identified at the junction of the QRS complex and the ST segment deviation. Therefore, there are discussions about whether these abnormalities represent ER, late depolarization, or other factors [100,101].
3.4. Late Ventricular Potentials/Signal Averaged ECG

The term ventricular late potentials (LP) refers to low-amplitude, short-duration signals that occur after the QRS complex. For their detection, a special electrocardiographic technic, signal-averaged electrocardiography (SAECG), is used, which allows reducing interference and revealing low-amplitude signals at the end of the QRS complex.

The presence of LP is associated with scars and structural abnormalities of myocardium, i.e., structural conditions for re-entry, and they may indicate a predisposition to ventricular arrhythmias and sudden cardiac death [102–105]. LPs were frequently observed also in patients with LVH [106–108]. However, their predictive value is also an open question [9,109].

3.5. Fragmented QRS Complex

Fractionation or fragmentation of the QRS complex (fragmented QRS complex—fQRS) is defined as the presence of R’ wave or notching of R or S wave in the presence of narrow QRS. It indicates heterogeneous depolarization of the ventricular myocardium that can occur due to ischemia, fibrosis, scar, or coronary microvascular dysfunction. Fragmented QRS complex is a significant and independent predictor of cardiovascular arrhythmia [110–113]. Fragmented QRS complex is frequently seen in patients with LVH, and it was reported to be associated with ventricular arrhythmia [114–116].

3.6. Body Surface Potential Mapping

Body surface potential mapping (BSPM) provides total information on the temporospatial distribution of electrical potentials on the surface of the chest. As compared to the limited information provided by the standard 12-lead ECG, it enables detection of local electrical events or local conduction disturbances, reflecting heterogeneity of underlying ventricular activation and repolarization [117]. Thus, it can identify the signs of susceptibility to arrhythmias and the site of origin of the arrhythmia. An additional advantage is the possibility to derive epicardial maps noninvasively (ECG imaging) from the distribution of surface potentials [118].

Although BSPM is a promising method, its utilization in clinical practice is still limited because of its demanding recording and interpretation, as well as of the need for standardization of lead systems and methods of BSPM data analysis.

Taken together, the interpretation of the above-mentioned ECG predictors of VA is related to altered electrophysiological processes and to our understanding of ventricular arrhythmia mechanisms. They are not specific for left ventricular hypertrophy, but they refer to underlying processes that can be present in a variety of cardiac pathology. In spite of their limitations, they represent challenging parameters of electrical remodeling. As was reviewed, LVH is associated with higher prevalence of these non-specific predictors of ventricular arrhythmia resulting from significant rebuilding of myocardium-affecting electogenesis that is potentially arrhythmogenic.

4. Waveform Interpretation in LVH

Paradoxically, there is a substantial gap between this detailed knowledge on molecular, subcellular, cellular and tissue levels on one hand, and clinical interpretation of ECG findings in LVH patients on the other. Consequently, the detailed knowledge on the electrical properties of hypertrophied myocardium contrasts with the clinical ECG diagnosis of LVH. The ECG diagnosis of LVH is mostly reduced on the increase in the QRS complex amplitude, so-called voltage criteria [119]. The anatomical aspect of LVH is stressed, and it is postulated that the bigger (hypertrophied) left ventricle generates a stronger cardioelectric field, which is reflected in the increase in the QRS complex amplitude. The possible effect of the electrical remodeling on the QRS complex is not considered.
4.1. ECG Criteria on LVH

Since LVH is defined as an increase in LV size/mass, the gold standard for comparative studies on LVH is left ventricular size/mass. The role of ECG in LVH diagnosis (ECG-LVH) is thus seen also in estimating the LVM. If there is an agreement between the increased LVM and the increased QRS complex amplitude, these results are assigned as true positive (which represents the minority of LVH cases); if there is a disagreement, these results are earmarked as false negative. The meta-analysis by Pewsner showed a wide range of sensitivity and specificity of ECG-LVH criteria [120], documenting the weakness of this approach.

The increased QRS complex amplitude is indeed associated with the increased risk of ventricular arrhythmia [7]. However, since the prevalence of ECG-LVH is lower as compared to the LVH detected by e.g., echocardiography, the calculated risk is also lower, which led to a questionable conclusion that ECG-LVH is less sensitive for ventricular arrhythmias. On the other hand, however, it was shown that even the so-called false negative ECG results have the prognostic value in CV risk assessment [121]; therefore, the focus only on the increased QRS voltage is questionable.

The Romhilt–Estes score (R–E) is a more complex ECG-LVH criterion and considers also other ECG abnormalities additional to the increased voltage [70]. It was shown that the individual components of R–E scores differ in predicting different CV outcomes and have independent predictive ability. It can be assumed that they reflect different pathophysiological aspects of the complex hypertrophic rebuilding [122].

It is obvious that if ECG records the electric field of the heart, the electrical properties of myocardium must be considered, especially in the case of ventricular arrhythmias, and the role of ECG-LVH diagnosis cannot be reduced and simplified to the estimation of the increase in LVM.

4.2. ECG Findings in LVH Patients

The increased QRS voltage is only one of the whole spectrum of QRS patterns observed in patients with LVH. It occurs in a minority of LVH patients, and its sensitivity ranges from 0% to 60% [120].

Additional to the increased QRS amplitude, there are other deviations from the normal QRS patterns in patients with LVH, such as the leftward shift of the electrical axis in the frontal plane, prolonged QRS duration, as well as ST segment and T wave changes. The intraventricular conduction defects, such as left bundle branch block (LBBB), left anterior fascicular block (LAFB), and especially the incomplete LBBB, are frequently observed. Finally, there are those false negative results, i.e., apparently normal QRS complexes (Figure 4).

Considering the multiple and interrelated changes affecting the electrical properties of hypertrophied myocardium, we used computer modeling to study their effect on the resultant QRS pattern [73]. The effect of slowed conduction velocity on the QTS pattern in three anatomical types of LVH was studied. As a composite parameter of electrical properties, we used slowed conduction velocity corresponding to published data [123–125].

It was shown that the increased LVM and the anatomical type of LVH are not the main factors affecting the QRS complex and that the increase in LVM does not result in proportional increase in QRS amplitude. It is the diffuse slowing of conduction velocity in combination with the anatomical types of LVH that affect QRS amplitude, duration, and morphology, and we observed the whole variety of QRS patterns that are seen in LVH patients. Interesting was also the effect of anatomical changes and/or conduction velocity slowing on the clinical ECG-LVH criteria that were affected differently. We also showed that QRS patterns consistent with QRS complex changes observed in patients with LVH can be seen also in a normal-sized heart if the slowed conduction velocity is slowed.
Figure 4. The main factors influencing electrogenesis in left ventricular hypertrophy and the variety of ECG manifestations related to ventricular depolarization (QRS complex). fQRS: fragmented QRS complex; LP: late ventricular potential; ER: early repolarization; LAD: left axis deviation; LAFB: left anterior fascicular block; LBBB: left bundle branch block.

A frequent finding in different types of left ventricular is midwall fibrosis [26,27,126]. We showed in a simulation study that the midwall slowing in conduction velocity also modified the QRS complex morphology and resulted in QRS patterns usually interpreted as the effect of left ventricular hypertrophy, i.e., the increase in LV mass [127].

Summarizing, on one hand, there are documented details on molecular, structural, and functional changes in LVH; on the other hand, there is a simplified mechanistic approach used for diagnosing and evaluating/monitoring the effect of therapy. When talking about remodeling LVH in clinical practice, the anatomical types of LVH are considered: concentric remodeling, concentric hypertrophy, and eccentric hypertrophy. Although ECG is the unique method recording the electrical phenomena, in the case of LVH, its role is shifted to the estimation of anatomical aspects of LVH.

The possibilities for evaluating the effect of therapy in LVH in clinical practice are limited to imaging methods and ECG (if not talking about clinical outcomes). What is the desired effect of the therapy in LVH in relation to the ventricular arrhythmias? The reduction of the LV mass? The reduction of the QRS voltage? How are they related to expected effects of targeted therapy that are based on the detailed knowledge of the molecular processes? How is this detailed knowledge translated into the ECG diagnosis of LVH? To detect their early manifestation in electrocardiogram prior to the manifestation of ventricular arrhythmia? If left ventricular hypertrophy is the therapeutic target, then how does one best combine the arrhythmia biomarkers for monitoring the effect of therapy [128]?

5. Conclusions

There is a remarkable gap in knowledge between molecular details on one hand and diagnostic possibilities and ECG interpretation in clinical practice in the case of left ventricular hypertrophy on the other. It is documented that in LVH, the myocardium is considerably changed, and these changes are potentially arrhythmogenic. To decrease this gap is a real challenge for electrocardiography as well as for basic scientists. Electrocardiology needs to go beyond traditional diagnostic categories and to
reconsider the classical interpretation of QRS-T patterns. Electrocardiology needs to focus primarily on
the function of the heart as a source of cardio-electric field, considering and incorporating the current
knowledge in electrophysiology and electrical remodeling under pathological conditions. There are
no such results as false of confounding; it is the false expectation and lack of understanding of the
processes, and consequently, the meaningful information is so far neglected. Basic scientists need to
understand clinical challenges and help translate the extensive knowledge on molecular mechanisms
into relevant clinical categories.

Funding: This research was partly funded by the Slovak Research and Development Agency under contract
No. APVV-16-0158 and research grants of the Ministry of Education, Science, Research and Sport of the Slovak
Republic VEGA 2/0125/19 and VEGA 1/0338/17.

Acknowledgments: The author thanks Barbara Szeiffova Bacova for providing electron microscopic and
immunofluorescence images (Figures 1 and 2).

Conflicts of Interest: The author declares no conflict of interest.

References
1. Calkins, H.; Corrado, D.; Marcus, F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy.
Circulation 2017, 136, 2068–2082. [CrossRef] [PubMed]
2. Al-Khatib, S.M.; Stevenson, W.G.; Ackerman, M.J.; Bryant, W.J.; Callans, D.J.; Curtis, A.B.; Deal, B.J.;
Dickfeld, T.; Field, M.E.; Fonarow, G.C.; et al. 2017 AHA/ACC/HRS guideline for management of patients
with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College
of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm
Society. Heart Rhythm 2018, 15, e73–e189. [PubMed]
3. Epstein, A.E.; DiMarco, J.P.; Ellenbogen, K.A.; Estes, N.A., III; Freedman, R.A.; Gettes, L.S.; Gillinov, A.M.;
Gregoratos, G.; Hammill, S.C.; Hayes, D.L.; et al. 2012 ACCF/AHA/HRS focused update incorporated into the
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2013, 61, e6–75. [PubMed]
4. Tang, A.S.; Ross, H.; Simpson, C.S.; Mitchell, L.B.; Dorian, P.; Goeree, R.; Hoffmaster, B.; Arnold, M.; Talajic, M.
Canadian Heart Rhythm S, Canadian Cardiovascular, S. Canadian Cardiovascular Society/Canadian Heart
Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can. J. Cardiol.
2005, 21 (Suppl. SA), 11A–18A.
5. Goldenberg, I.; Vyas, A.K.; Hall, W.J.; Moss, A.J.; Wang, H.; He, H.; Zareba, W.; McNitt, S.; Andrews, M.L.;
Madit-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients
with ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 2008, 51, 288–296. [CrossRef]
6. Chatterjee, S.; Bavishi, C.; Sardar, P.; Agarwal, V.; Krishnamoorthy, P.; Grodzicki, T.; Messerli, F.H. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am. J. Cardiol. 2014, 114,
1049–1052. [CrossRef]
7. Levy, D.; Anderson, K.M.; Savage, D.D.; Balkus, A.; Kannel, W.B.; Castelli, W.P. Risk of ventricular arrhythmias
in left ventricular hypertrophy: The Framingham Heart Study. Am. J. Cardiol. 1987, 60, 560–565. [CrossRef]
8. Shenasa, M.; Shenasa, H.; El-Sherif, N. Left ventricular hypertrophy and arrhythmogenesis. Card Electrophysiol.
Clin. 2015, 7, 207–220. [CrossRef]
9. Franchi, F.; Lazzari, C.; La Villa, G.; Barletta, G.; Del Bene, R.; Buzzelli, G. Cardiac autonomic modulation and
incidence of late potentials in essential hypertension: Role of age, sex, ventricular mass and remodeling.
J. Hum. Hypertens. 1998, 12, 13–20. [CrossRef]
10. Sorgato, A.; Faggiano, P.; Aurigemma, G.P.; Rusconi, C.; Gaasch, W.H. Ventricular arrhythmias in adult aortic
stenosis: Prevalence, mechanisms, and clinical relevance. Chest 1998, 113, 482–491. [CrossRef]
11. Wolfe, R.R.; Driscoll, D.J.; Gersony, W.M.; Hayes, C.J.; Keane, J.F.; Kidd, L.; O’Fallon, W.M.; Pieroni, D.R.;
Weidman, W.H. Arrhythmias in patients with valvar aortic stenosis, valvar pulmonary stenosis, and
ventricular septal defect. Results of 24-h ECG monitoring. Circulation 1993, 87 (Suppl. S2), 189–101. [PubMed]
12. Tempio, D.; Pruiti, G.P.; Conti, S.; Romano, S.A.; Tavano, E.; Capodanno, D.; Liotta, C.; Di Grazia, A.; Tamburino, C.; Calvi, V. Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation. 
Europace 2015, 17, 1136–1145. [CrossRef] [PubMed]

13. Kawamura, K.; Kashii, C.; Imamura, K. Ultrastructural changes in hypertrophied myocardium of spontaneously hypertensive rats. 
Jpn Circ. J. 1976, 40, 1119–1145. [CrossRef] [PubMed]

14. McCrossan, Z.A.; Billeter, R.; White, E. Transmural changes in size, contractile and electrical properties of SHR left ventricular myocytes during compensated hypertrophy. 
Cardiovasc. Res. 2004, 63, 283–292. [CrossRef] [PubMed]

15. Main, M.C.; Bryant, S.M.; Hart, G. Regional differences in action potential characteristics and membrane currents of guinea-pig left ventricular myocytes. 
Exp. Physiol. 1998, 83, 747–761. [CrossRef] [PubMed]

16. Gutstein, D.E.; Morley, G.E.; Tammadon, H.; Vaidaya, D.; Schneider, M.D.; Chen, J.; Chien, K.R.; Stuhlman, H.; Fishman, G.I. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. 
Circ. Res. 2001, 88, 333–339. [CrossRef] [PubMed]

17. Van Rijen, H.V.M.; Eckardt, D.; Degen, J.; Theis, M.; Ott, T.; Willecke, K.; Jongsma, H.J.; Opthof, T.; de Bakker, J.M. Slow conduction and enhanced anisotropy increase the propensity for ventricular tachyarrhythmias in adult mice with induced deletion of connexin43. 
Circulation 2004, 109, 1048–1055. [CrossRef]

18. Sawada, K.; Kawamura, K. Architecture of myocardial cells in human cardiac ventricles with concentric and eccentric hypertrophy as demonstrated by quantitative scanning electron microscopy. 
Heart Vessel. 1991, 6, 129–142. [CrossRef]

19. Yamamoto, S.; James, T.N.; Sawada, K.; Okabe, M.; Kawamura, K. Generation of new intercellular junctions between cardiocytes. A possible mechanism compensating for mechanical overload in the hypertrophied human adult myocardium. 
Circ. Res. 1996, 78, 362–370. [CrossRef]

20. Okabe, M.; Kawamura, K.; Terasaki, F.; Hayashi, T. Remodeling of cardiomyocytes and their branches in juvenile, adult, and senescent spontaneously hypertensive rats and Wistar Kyoto rats: Comparative morphometric analyses by scanning electron microscopy. 
Heart Vessel. 1999, 14, 15–28. [CrossRef]

21. Rithalia, A.; Hopkins, P.M.; Harrison, S.M. Effects of halothane on action potential configuration in subendocardial and sub-epicardial myocytes from normotensive and hypertensive rat left ventricle. 
Br. J. Anaesth. 2001, 90, 501–503. [CrossRef] [PubMed]

22. Spach, M.S.; Heidlage, J.F.; Dolber, P.C.; Barr, R.C. Electrophysiological effects of remodeling cardiac gap junctions and cell size. Experimental and model studies of normal cardiac growth. 
Circ. Res. 2000, 86, 302–311. [CrossRef] [PubMed]

23. Joyner, R.W. Effects of the discrete pattern of electrical coupling on propagation through an electrical syncytium. 
Circ. Res. 1982, 50, 192–200. [CrossRef] [PubMed]

24. Kucera, J.P.; Rudy, Y. Mechanistic insight into very slow conduction in branching cardiac tissue. A model study. 
Circ. Res. 2001, 89, 799–806. [CrossRef]

25. Nakamura, M.; Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. 
Nat. Rev. Cardiol. 2018, 15, 387–407. [CrossRef]

26. Dweck, M.R.; Joshi, S.; Murigu, T.; Alpendurada, F.; Jabbour, A.; Melina, G.; Banya, W.; Roussin, L; Raza, S.; et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. 
J. Am. Coll. Cardiol. 2011, 58, 1271–1279. [CrossRef]

27. Levy, F.; Taylor, R.J.; Foley, P.W.; Umar, F.; Mulligan, L.J.; Patel, K.; Stegemann, B.; Haddad, T.; Smith, R.E.; Prasad, S.K. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. 
J. Am. Coll. Cardiol. 2012, 60, 1659–1667. [CrossRef]

28. Shenasa, M.; Shenasa, H. Hypertension, left ventricular hypertrophy, and sudden cardiac death. 
Int J. Cardiol. 2017, 237, 60–63. [CrossRef]

29. Salvador, A.M.; Nevers, T.; Velázquez, F.; Aronovitz, M.; Wang, B.; Abadía Molina, A.; Jaffe, I.Z.; Karas, R.H.; Blanton, R.M.; Alcaide, P. Intercellular adhesion molecule 1 regulates left ventricular leukocyte infiltration, cardiac remodeling, and function in pressure overload-induced heart failure. 
J. Am. Heart Assoc. 2016, 5, e003126. [CrossRef]
52. Wiegerinck, R.F.; Verkerk, A.O.; Belterman, C.N.; van Veen, T.A.; Baartscheer, A.; Opthof, T.; Wilders, R.; de Bakker, J.M.; Coronel, R. Larger cell size in rabbits with heart failure increases myocardial conduction velocity and QRS duration. *Circulation* **2006**, *113*, 806–813. [CrossRef] [PubMed]

53. Kostin, S.; Dammer, S.; Hein, S.; Kloekem, W.P.; Bauer, E.P.; Schaper, J. Connexin43 expression and distribution in compensated and decompensated cardiac hypertrophy in patients with aortic stenosis. *Cardiovasc. Res.* **2004**, *62*, 426–436. [CrossRef] [PubMed]

54. Peters, N.S.; Green, C.R.; Poole-Wilson, P.A.; Severs, N.J. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. *Circulation* **1993**, *88*, 864–875. [CrossRef] [PubMed]

55. Danik, S.B.; Liu, F.; Zhang, J.; Suk, H.J.; Morley, G.E.; Fishman, G.L.; Gutstein, D.E. Modulation of cardiac gap junction expression and arrhythmic susceptibility. *Circ. Res.* **2004**, *95*, 1035–1041. [CrossRef] [PubMed]

56. Dodge, S.M.; Beardslee, M.A.; Darrow, B.J.; Green, K.G.; Beyer, E.C.; Saffitz, J.E. Effect of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes. *J. Am. Coll. Cardiol.* **1998**, *32*, 800–807. [CrossRef]

57. Egan Benova, T.; Szeiffova Bacova, B.; Viczenczova, C.; Diez, E.; Barancik, M.; Tribulova, N. Protection of cardiac cell-to-cell coupling attenuate myocardial remodeling and proarrhythmia induced by hypertension. *Physiol. Res.* **2016**, *65* (Suppl. S1), S29–S42.

58. Tribulova, N.; Szeiffova Bacova, B.; Benova, T.; Viczenczova, C. Can we protect from malignant arrhythmias by modulation of cardiac cell-to-cell coupling? *J. Electrocardiol.* **2015**, *48*, 434–440. [CrossRef]

59. Radosinska, J.; Bacova, B.; Knezl, V.; Benova, T.; Zurmanova, J.; Soukup, T.; Arnostova, P.; Slezak, J.; Goncalvesova, E.; Tribulova, N. Dietary omega-3 fatty acids attenuate myocardial arrhythmogenic factors and propensity of the heart to lethal arrhythmias in a rodent model of human essential hypertension. *J. Hypertens.* **2013**, *31*, 1876–1885. [CrossRef]

60. Firek, L.; Weingart, R. Modification of gap junction conductance by divalent cations and protons in neonatal rat heart cells. *J. Mol. Cell Cardiol.* **1995**, *27*, 1633–1643. [CrossRef]

61. Marionneau, C.; Brunet, S.; Flagg, T.P.; Pilgram, T.K.; Demolombe, S.; Nerbonne, J.M. Distinct cellular and molecular mechanisms underlie functional remodeling of repolarizing K+ currents with left ventricular hypertrophy. *Circ. Res.* **2008**, *102*, 1406–1415. [CrossRef] [PubMed]

62. Antzelevitch, C.; Belardinelli, L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. *J. Cardiovasc. Electrophysiol.* **2006**, *17*, S79–S85. [CrossRef] [PubMed]

63. Thomas, S.P.; Kucera, J.P.; Bircher-Lehmann, L.; Rudy, Y.; Saffitz, J.E.; Kleber, A.G. Impulse propagation in synthetic strands of neonatal cardiac myocytes with genetically reduced levels of connexin43. *Circ. Res.* **2003**, *92*, 1209–1216. [CrossRef] [PubMed]

64. Josephson, M.E.; Anter, E. Substrate mapping for ventricular tachycardia: Assumptions and misconceptions. *JACC Clin. Electrophysiol.* **2015**, *1*, 341–352. [CrossRef]

65. Chávez-González, E.; Rodríguez Jiménez, A.E.; Moreno-Martínez, F.L. QRS duration and dispersion for predicting ventricular arrhythmias in early stage of acute myocardial infarction. *Med. Intensiva* **2017**, *41*, 347–355. [CrossRef]

66. Udink ten Cate, F.E.; Sreeram, N.; Brockmeier, K. The pathophysiological aspects and clinical implications of electrocardiographic parameters of ventricular conduction delay in repaired tetralogy of Fallot. *J. Electrocardiol.* **2014**, *47*, 618–624. [CrossRef]

67. Dao, D.T.; Hollander, S.A.; Rosenthal, D.N.; Dubin, A.M. QRS prolongation is strongly associated with life-threatening ventricular arrhythmias in children with dilated cardiomyopathy. *J. Heart Lung Transpl.* **2013**, *32*, 1013–1019. [CrossRef]

68. Morin, D.P.; Otkarinen, L.; Viitasalo, M.; Toivonen, L.; Nieminen, M.S.; Kjeldsen, S.E.; Dahlöf, B.; John, M.; Devereux, R.B.; Okin, P.M. QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: The LIFE study. *Eur. Heart J.* **2009**, *30*, 2908–2914. [CrossRef]

69. Romhilt, D.W.; Estes, E.H., Jr. A point-score system for the ECG diagnosis of left ventricular hypertrophy. *Am. Heart J.* **1968**, *75*, 752–758. [CrossRef]

70. Li, Z.; Dahlöf, B.; Okin, P.M.; Kjeldsen, S.E.; Wachtell, K.; Ibsen, H.; Nieminen, M.S.; Jern, S.; Devereux, R.B. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension study. *J. Hypertens.* **2008**, *26*, 1244–1249. [CrossRef]
71. Prihadi, E.A.; Leung, M.; Völlema, E.M.; Ng, A.C.T.; Ajmone Marsan, N.; Bax, J.J.; Delgado, V. Prevalence and prognostic relevance of ventricular conduction disturbances in patients with aortic stenosis. *Am. J. Cardiol.* 2017, 120, 2226–2232. [CrossRef] [PubMed]

72. Erne, P.; Iglesias, J.F.; Urban, P.; Eberli, F.R.; Rickli, H.; Simon, R.; Fischer, T.A.; Radovanovic, D. Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice. *Am. Heart J.* 2017, 84, 106–113. [CrossRef] [PubMed]

73. Bacharova, L.; Szathmary, V.; Kovalcik, M.; Mateasik, A. Primary and secondary T wave changes in LVH: A model study. *J. Electrocardiol.* 2010, 43, 200–208. [CrossRef] [PubMed]

74. Bacharova, L.; Szathmary, V.; Mateasik, A. Electrocardiographic patterns of left bundle-branch block caused by intraventricular conduction impairment in working myocardium: A model study. *J. Electrocardiol.* 2011, 44, 768–778. [CrossRef] [PubMed]

75. Xiang, L.; Zhong, A.; You, T.; Chen, J.; Xu, W.; Shi, M. Prognostic significance of right bundle branch block for patients with acute myocardial infarction: A Systematic Review and Meta-Analysis. *Med. Sci. Monit.* 2016, 22, 998–1004. [CrossRef] [PubMed]

76. Al Rajoub, B.; Noureddine, S.; El Chami, S.; Haidar, M.H.; Itani, B.; Zaiter, A.; Akl, E.A. The prognostic value of a new left bundle branch block in patients with acute myocardial infarction: A systematic review and meta-analysis. *Heart Lung.* 2017, 46, 85–91. [CrossRef]

77. Li, Z.B.; Wachtell, K.; Okin, P.M.; Gerdts, E.; Liu, J.E.; Nieminen, M.S.; Jern, S.; Dahlöf, B.; Devereux, R.B. Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: The LIFE study. *J. Hum. Hypertens.* 2004, 18, 397–402. [CrossRef]

78. Buxton, A.E.; Sweeney, M.O.; Wathen, M.S.; Josephson, M.E.; Otterness, M.F.; Hogan-Miller, E.; Stark, A.J.; Degroot, P.J.; Pain, F.R.; III. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. *J. Am. Coll. Cardiol.* 2005, 46, 310–316. [CrossRef]

79. Singh, J.P.; Hall, W.J.; McNitt, S.; Wang, H.; Daubert, J.P.; Zareba, W.; Ruskin, J.N.; Moss, A.J.; Madit-II Investigators. Investigators M-I. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: Findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). *J. Am. Coll. Cardiol.* 2005, 46, 1712–1720. [CrossRef]

80. Niemeijer, M.N.; van den Berg, M.E.; Eijgelsheim, M.; van Herpen, G.; Stricker, B.H.; Kors, J.A.; Rijnbeek, P.R. Influence of the left ventricular types on QT intervals in hypertensive patients. *Anatol. J. Cardiol.* 2015, 15, 33–39. [CrossRef] [PubMed]

81. Oikarinen, L.; Nieminen, M.S.; Toivonen, L.; Viitasalo, M.; Wachtell, K.; Papademetriou, V.; Jern, S.; Dahlöf, B.; Devereux, R.B.; Okin, P.M. LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: The Losartan Intervention for Endpoint Reduction (LIFE) study. *Am. Heart J.* 2003, 145, 919–925. [CrossRef]

82. Oikarinen, L.; Nieminen, M.S.; Viitasalo, M.; Toivonen, L.; Jern, S.; Dahlöf, B.; Devereux, R.B.; Okin, P.M. LIFE Study Investigators. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study. *Hypertension* 2004, 43, 1029–1034. [CrossRef]

83. Bacharova, L.; Szathmary, V.; Mateasik, A. Primary and secondary T wave changes in LVH: A model study. *J. Electrocardiol.* 2010, 43, 624–633. [CrossRef]

84. Lu, H.R.; Yan, G.X.; Gallacher, D.J. A new biomarker–index of cardiac electrophysiological balance (iCEB) –plays an important role in drug-induced cardiac arrhythmias: Beyond QT prolongation and torsade de pointes (TdPs). *J. Pharm. Toxicol. Methods* 2013, 68, 250–259. [CrossRef]

85. Robyns, T.; Lu, H.R.; Gallacher, D.J.; Garweg, C.; Ector, J.; Willems, R.; Janssens, S.; Nuyens, D. Evaluation of cardio-electrophysiological balance (iCEB) as a new biomarker for the identification of patients at increased arrhythmic risk. *Ann. Noninvasive Electrocardiol.* 2016, 21, 294–304. [CrossRef]
88. Haigney, M.C.; Zareba, W.; Gentlesk, P.J.; Goldstein, R.E.; Illovsky, M.; McNitt, S.; Andrews, M.L.; Moss, A.J. Multicenter Automatic Defibrillator Implantation Trial Illi. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J. Am. Coll Cardiol. 2004, 44, 1481–1487. [CrossRef] [PubMed]
89. Miragoli, M.; Goldoni, M.; Demola, P.; Paterlini, A.; Li Calzi, M.; Gioia, M.I.; Visioli, F.; Rossi, S.; Pela, G. Left ventricular geometry correlates with early repolarization pattern in adolescent athletes. Scand. J. Med. Sci. Sports 2019, 29, 1727–1735. [CrossRef]
90. Háissaguerre, M.; Derval, N.; Sacher, F.; Jesel, L.; Deisenhofer, I.; de Roy, L.; Pasquié, J.L.; Nogami, A.; Babuty, D.; Yli-Mayry, S.; et al. Sudden cardiac arrest associated with early repolarization. N Engl. J. Med. 2008, 358, 2016–2023. [CrossRef]
91. Ali Diab, O.; Abdel-Hafez Allam, R.M.; Mohamed, H.G.; Mohamed, T.R.; Abel-Hafeez Khalid, S. Early repolarization pattern is associated with increased risk of early ventricular arrhythmias during acute ST segment elevation myocardial infarction. Ann. Noninvasive Electrocardiol. 2015, 20, 474–480. [CrossRef] [PubMed]
92. Pranata, R.; Yonas, E.; Vania, R.; Raharjo, S.B.; Siswanto, B.B.; Setianto, B. Electrocardiographic early repolarization is associated with future ventricular arrhythmia after acute myocardial infarction-Systematic Review and Meta-Analysis. J. Arrhythm. 2019, 35, 626–635. [CrossRef] [PubMed]
93. Naruse, Y.; Tada, H.; Harimura, Y.; Ishibashi, M.; Noguchi, Y.; Sato, A.; Hoshi, T.; Sekiguchi, Y.; Aonuma, K. Early repolarization increases the occurrence of sustained ventricular tachyarrhythmias and sudden death in the chronic phase of an acute myocardial infarction. Circ. Arrhythm. Electrophysiol. 2014, 7, 626–632. [CrossRef] [PubMed]
94. Dalos, D.; Fiedler, L.; Radojevic, J.; Sponder, M.; Dichtl, W.; Schukro, C. Prevalence of early repolarization syndrome and long-term clinical outcome in patients with the diagnosis of idiopathic ventricular fibrillation. Heart Vessel. 2019, 34, 625–631. [CrossRef]
95. Cheng, Y.J.; Li, Z.Y.; Yao, F.J.; Xu, X.J.; Ji, C.C.; Chen, X.M.; Liu, L.J.; Lin, X.X.; Yao, H.; Wu, S.H. Early repolarization is associated with a significantly increased risk of ventricular arrhythmias and sudden cardiac death in patients with structural heart diseases. Heart Rhythm. 2017, 14, 1157–1164. [CrossRef] [PubMed]
96. Yan, G.X.; Antzelevitch, C. Cellular basis for the electrocardiographic J wave. Circulation 1996, 93, 372–379. [CrossRef]
97. Gussak, I.; Antzelevitch, C. Early repolarization syndrome: Clinical characteristics and possible cellular and ionic mechanisms. J. Electrocardiol. 2000, 33, 299–309. [CrossRef]
98. Antzelevitch, C.; Yan, G.X. J wave syndromes. Heart Rhythm. 2010, 7, 549–558. [CrossRef]
99. Trenkwalder, T.; King, R.; Kaess, B.M.; Hengstenberg, C.; Schunkert, H.; Ittermann, T.; Felix, S.B.; Busch, M.; Dörr, M.; Reinhard, W. Ventricular and supraventricular ectopy in subjects with early repolarization. Am. J. Cardiol. 2017, 120, 92–97. [CrossRef]
100. Babuty, D.; Yli-Mayry, S.; et al. Sudden cardiac arrest associated with early repolarization. J. Am. Coll Cardiol. 2019, 73, 2063–2065. [CrossRef]
101. Ghosh, S.; Cooper, D.H.; Vijayakumar, R.; Zhang, J.; Pollak, S.; Háissaguerre, M.; Rudy, Y. Early repolarization associated with sudden death: Insights from noninvasive electrocardiographic imaging. Heart Rhythm 2010, 7, 534–537. [CrossRef] [PubMed]
102. El-Sherif, N.; Turitto, G.; Fontaine, J.M. Risk stratification of patients with complex ventricular arrhythmias. Value of ambulatory electrocardiographic recording, programmed electrical stimulation and the signal-averaged electrocardiogram. Herz 1988, 13, 204–214. [PubMed]
103. Marstrand, P.; Axelsson, A.; Thune, J.J.; Veijstrup, N.; Pehrson, S.; Bundgaard, H.; Theilade, J. Late potentials and their correlation with ventricular structure in patients with ventricular arrhythmias. Pacing Clin. Electrophysiol. 2017, 40, 1466–1471. [CrossRef] [PubMed]
104. Irie, T.; Yu, R.; Bradfield, J.S.; Vaseghi, M.; Buch, E.F.; Ajijola, O.; Macias, C.; Fujimura, O.; Mandapati, R.; Boyle, N.G.; et al. Relationship between sinus rhythm late activation zones and critical sites for scar-related ventricular tachycardia: Systematic analysis of isochronal late activation mapping. Circ. Arrhythm. Electrophysiol. 2015, 8, 390–399. [CrossRef] [PubMed]
105. Santangeli, P.; Marchlinski, F.E. Substrate mapping for unstable ventricular tachycardia. Heart Rhythm 2016, 13, 569–583. [CrossRef]
106. Wojcieszko, A.; Loboz-Grudzień, K.; Jaroch, J. Signal averaged ECG in different patterns of left ventricular hypertrophy and geometry in hypertension. Kardiol. Pol. 2003, 58, 335–343. [CrossRef] [PubMed]
107. Maffei, P.; Martini, C.; Milanesi, A.; Corfini, A.; Mioni, R.; de Carlo, E.; Menegazzo, C.; Scanarini, M.; Vettor, R.; Federspil, G.; et al. Late potentials and ventricular arrhythmias in acromegaly. *Int. J. Cardiol.* 2005, 104, 197–203. [CrossRef]

108. Palmiero, P.; Maiello, M. Arrhythmic risk in essential hypertension: Late potentials. *Minerva Cardioangiol.* 2004, 52, 1–8.

109. Goldberger, J.J.; Cain, M.E.; Hohnloser, S.H.; Kadish, A.H.; Knight, B.P.; Lauer, M.S.; Maron, B.J.; Page, R.L.; Passman, R.S.; Siscovick, D.; et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death. A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. *J. Am. Coll. Cardiol.* 2008, 52, 1179–1199.

110. Deyell, M.W.; Krahn, A.D.; Goldberger, J.J. Sudden cardiac death risk stratification. *Circ. Res.* 2015, 116, 1907–1918. [CrossRef]

111. Bokma, J.P.; Winter, M.M.; Vehmeijer, J.T.; Vliegen, H.W.; van Dijk, A.P.; van Melle, J.P.; Meijboom, F.J.; Post, M.C.; Zwinderman, A.H.; Mulder, B.J.; et al. QRS fragmentation is superior to QRS duration in predicting mortality in adults with tetralogy of Fallot. *Heart* 2017, 103, 666–671. [CrossRef] [PubMed]

112. Pietrasik, G.; Zaręba, W. QRS fragmentation: Diagnostic and prognostic significance. *Cardiol. J.* 2012, 19, 114–121. [CrossRef] [PubMed]

113. Das, M.K.; Maskoun, W.; Shen, C.; Michael, M.A.; Suradi, H.; Desai, M.; Subbarao, R.; Bhakta, D. Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy. *Heart Rhythm.* 2010, 7, 74–80. [CrossRef] [PubMed]

114. Kadi, H.; Kevser, A.; Ozturk, A.; Koc, F.; Ceyhan, K. Fragmented QRS complexes are associated with increased left ventricular mass in patients with essential hypertension. *Ann. Noninvasive Electrocardiol.* 2013, 18, 547–554. [CrossRef] [PubMed]

115. Eyuboglu, M. Fragmented QRS as a marker of myocardial fibrosis in hypertension: A systematic review. *Curr. Hypertens Rep.* 2019, 21, 73. [CrossRef] [PubMed]

116. Bekar, L.; Kalçık, M.; Kilci, H.; Çelik, O.; Yetim, M.; Doğan, T.; Önalan, O. Presence of fragmented QRS may be associated with complex ventricular arrhythmias in patients with essential hypertension. *J. Electrocardiol.* 2019, 55, 20–25. [CrossRef]

117. De Ambroggi, L.; Corlan, A.D. Clinical use of body surface potential mapping in cardiac arrhythmias. *Anatol. J. Cardiol.* 2007, 7 (Suppl. S1), 8–10.

118. Burns, J.E.; Taccardi, B.; Rudy, Y. A noninvasive imaging modality for cardiac arrhythmias. *Circulation* 2000, 102, 2152–2158. [CrossRef]

119. Hancock, E.W.; Deal, B.J.; Mirvis, D.M.; Okin, P.; Klugfield, P.; Gettes, L.S.; Bailey, J.J.; Childers, R.; Gorgels, A.; Josephson, M.; et al. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram. Part V: Electrocardiogram changes associated with cardiac chamber hypertrophy. A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. *J. Am. Coll. Cardiol.* 2009, 53, 992–1002.

120. Pewsner, D.; Jüni, P.; Egger, M.; Battaglia, M.; Sundström, J.; Bachmann, L.M. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: Systematic review. *BMJ* 2007, 335, 711. [CrossRef]

121. Bacharova, L.; Chen, H.; Estes, E.H.; Mateasik, A.; Bluemke, D.A.; Lima, J.A.; Burke, G.L.; Soliman, E.Z. Determinants of discrepancies in detection and comparison of the prognostic significance of left ventricular hypertrophy by electrocardiogram and cardiac magnetic resonance imaging. *Am. J. Cardiol.* 2015, 115, 515–522. [CrossRef] [PubMed]

122. Estes, E.H.; Zhang, Z.M.; Li, Y.; Tereshchenko, L.G.; Soliman, E.Z. Individual components of the Romhilt-Estes left ventricular hypertrophy score differ in their prediction of cardiovascular events: The Atherosclerosis Risk in Communities (ARIC) study. *Am. Heart J.* 2015, 170, 1220–1226. [CrossRef] [PubMed]

123. McIntyre, H.; Fry, C.H. Abnormal action potential conduction in isolated human hypertrophied left ventricular myocardium. *J. Cardiovasc. Electrophysiol.* 1997, 8, 887–894. [CrossRef] [PubMed]
124. Cooklin, M.; Wallis, W.R.; Sheridan, D.J.; Fry, C.H. Conduction velocity and gap junction resistance in hypertrophied, hypoxic guinea-pig left ventricular myocardium. *Exp. Physiol.* 1998, 83, 763–770. [CrossRef] [PubMed]

125. Carey, P.A.; Turner, M.; Fry, C.H.; Sheridan, D.J. Reduced anisotropy of action potential conduction in left ventricular hypertrophy. *J. Cardiovasc. Electrophysiol.* 2001, 12, 830–835. [CrossRef] [PubMed]

126. Moreo, A.; Ambrosio, G.; De Chiara, B.; Tran, T.; Raman, S.V. Influence of midwall fibrosis on diastolic dysfunction in non-ischemic cardiomyopathy. *Int. J. Cardiol.* 2013, 163, 342–344. [CrossRef] [PubMed]

127. Bacharova, L.; Szathmary, V.; Svehlikova, J.; Mateasik, A.; Gyhagen, J.; Tysler, M. The effect of conduction velocity slowing in left ventricular midwall on the QRS complex morphology: A simulation study. *J. Electrocardiol.* 2016, 49, 164–170. [CrossRef]

128. Brooks, J.E.; Soliman, E.Z.; Upadhyya, B. Is left ventricular hypertrophy a valid therapeutic target? *Curr. Hypertens Rep.* 2019, 21, 47. [CrossRef]